Galmed Pharmaceuticals (EOCN) Return on Equity [ROE] (2014 - 2026)
Galmed Pharmaceuticals' Return on Equity [ROE] came in at 61.81% for Q2 2026, up 53.31 percentage points from 8.50% a year earlier and up 49.98 percentage points from the prior quarter.
Powered by 
Analysis
Galmed Pharmaceuticals (EOCN) Return on Equity [ROE] (2014 - 2026) Analysis & Trends
For FY2025, Galmed Pharmaceuticals' Return on Equity [ROE] was 63.51%, up 13.99 percentage points from FY2024.
- Return on Equity [ROE] carries a five-year change of +13.45 percentage points (FY2020 to FY2025).
- Going back by year, Return on Equity [ROE] was 49.52% in FY2024 (+1.02 pp), 48.50% in FY2023 and 481.99% in FY2021 (+431.93 pp).
- The Q2 2026 figure represents the highest quarterly Return on Equity [ROE] since Q2 2023.
- Year-over-year, Return on Equity [ROE] increased in two of the last six quarters, with an average year-over-year change of -12.92 percentage points.
- The fastest year-over-year change in Return on Equity [ROE] over five years came in Q4 2021 (a gain of 858.49 percentage points), and the weakest in Q4 2022 (a drop of 790.42 percentage points).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | - |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 84.40% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 4.97% |
| 10 | Galmed Pharmaceuticals | 420,034.32 | 420,034.32 | - | 61.81% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 61.81% |
| Mar 31, 2026 | 11.83% |
| Jun 30, 2025 | 8.50% |
| Mar 31, 2025 | 1.13% |
| Dec 31, 2024 | 2.17% |
| Sep 30, 2024 | 40.10% |
| Jun 30, 2024 | 46.09% |
| Mar 31, 2024 | 46.31% |
| Dec 31, 2023 | 45.14% |
| Sep 30, 2023 | 55.87% |
| Jun 30, 2023 | 98.40% |
| Mar 31, 2023 | 106.89% |
| Dec 31, 2022 | 126.42% |
| Sep 30, 2022 | 128.80% |
| Jun 30, 2022 | 115.95% |
| Dec 31, 2021 | 916.84% |
| Sep 30, 2021 | 85.77% |
| Jun 30, 2021 | 71.20% |
| Mar 31, 2021 | 64.35% |
| Dec 31, 2020 | 58.35% |
API Access
Galmed Pharmaceuticals Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=EOCN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "EOCN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=EOCN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();